Influence of N-acetylcysteine on FEV1, VC, DLCO, PaO2 in patients with chronic obstructive pulmonary disease and pulmonary interstitial fibrosis
10.3760/cma.j.issn.1008-6706.2019.21.003
- VernacularTitle: 大剂量N-乙酰半胱氨酸对慢性阻塞性肺疾病合并肺间质纤维化患者肺功能、血清指标及血气指标的影响
- Author:
Yuzhi WU
1
;
Aiping WU
Author Information
1. Department of Respiration, the People's Hospital of Shanxi Province, Taiyuan, Shanxi 030012, China
- Publication Type:Journal Article
- Keywords:
Pulmonary fibrosis;
Pulmonary disease, chronic obstructive;
Vital capacity;
Vascular endothelial growth factor;
Transforming growth factor;
Arterial oxygen partial pressure;
Diffusion capacity of lung carbon monoxide;
N-acetylcysteine
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(21):2569-2573
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the influence of N-acetylcysteine on forced expiratory volume in one second(FEV1), vital capacity(VC), diffusion capacity of lung carbon monoxide(DLCO), arterial oxygen partial pressure(PaO2) in patients with chronic obstructive pulmonary disease(COPD) and pulmonary interstitial fibrosis.
Methods:From January 2015 to July 2017, 140 COPD patients complicated with pulmonary interstitial fibrosis in the People's Hospital of Shanxi Province were chosen as study objects, and they were divided into control group and research group according to the digital table, with 70 cases in each group.The control group was treated with routine treatment, while the research group was treated with N-acetylcysteine.After treatment, the treatment effects, VC, FEV1, PaO2, DLCO, TGF-β and VEGF between the two groups were compared.
Results:The total effective rate of the research group was 82.86%(58/70), which of the control group was 58.57%(41/70), the difference was statistically significant (χ2=9.968, P<0.05). Before treatment, the pulmonary function between the two groups had no statistically significant difference(t=0.082, 0.028, 0.421, 0.155, all P>0.05). After treatment, the FEV1[(59.03±15.02)% vs.(53.35±13.71)%], VC[(69.95±11.83)% vs.(65.21±11.65)%], DLCO[(68.92±11.56)% vs.(64.01±11.34)%] and PaO2[(68.79±5.38)mmHg vs.(62.37±6.14)mmHg]of the research group were higher than those of the control group, the differences were statistically significant (t=2.337, 2.389, 2.537, 6.580, all P<0.05). Before treatment, the TGF-β and VEGF levels between the two groups had no statistically significant differences(t=1.230, 0.016, all P>0.05). After treatment, the VEGF[(0.32±0.04)ng/L vs.(0.44±0.05)ng/L] and TGF-β[(271.16±35.21)ng/L vs.(345.13±39.08)ng/L] levels of the research group were lower than those of the control group, the differences were statistically significant (t=11.765, 15.680, all P<0.05). There was no statistically significant difference in the incidence rate of adverse reactions between the two groups(1.43% vs 4.28%, χ2=2.323, P>0.05).
Conclusion:Large dose of N-acetylcysteine can effectively improve the TGF-β and VEGF levels of COPD patients complicated with pulmonary interstitial fibrosis, and promote its pulmonary function, with good safety.
